The effects of empagliflozin, dietary energy restriction, or both on appetite‐regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double‐blind, placebo‐controlled trial

AIM: To assess the impact of the sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor empagliflozin (25 mg once‐daily), dietary energy restriction, or both combined, on circulating appetite‐regulatory peptides in people with type 2 diabetes (T2D) and overweight or obesity. MATERIALS AND METHODS: In a d...

Descripción completa

Detalles Bibliográficos
Autores principales: Sargeant, Jack A., King, James A., Yates, Thomas, Redman, Emma L., Bodicoat, Danielle H., Chatterjee, Sudesna, Edwardson, Charlotte L., Gray, Laura J., Poulin, Benoit, Waheed, Ghazala, Waller, Helen L., Webb, David R., Willis, Scott A., Wilding, John P. H., Khunti, Kamlesh, Stensel, David J., Davies, Melanie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541107/
https://www.ncbi.nlm.nih.gov/pubmed/35441435
http://dx.doi.org/10.1111/dom.14721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541107/
https://www.ncbi.nlm.nih.gov/pubmed/35441435
http://dx.doi.org/10.1111/dom.14721

Ejemplares similares